Evidence map›Paper›PMID 39100848›Full record

ArticleTranslational andrology and urology2024

Imposter among us: field cancerization in the bladder.

Daniel J Rodden, Ella H Chung, Rea Pittie, David T Miyamoto

Abstract readEditorialComment
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Daniel J RoddenKrantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
Ella H ChungKrantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
Rea PittieKrantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
David T MiyamotoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.ORCID https://orcid.org/0000-0003-3692-8823

Funding

Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancerR01CA259007 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MIYAMOTO, DAVID T. · 2022 to 2025
$3.0M
NCI NIH HHS R01 CA259007
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bladder cancerField cancerizationprogrammed cell death protein 1 (PD-1)T-cell exhaustionurinary tumor DNA

Identifiers

PMID39100848
PMCPMC11291423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.